Revolution Medicines, Inc. (NASDAQ:RVMD) Director Barbara Weber Sells 5,200 Shares

Revolution Medicines, Inc. (NASDAQ:RVMD) Director Barbara Weber sold 5,200 shares of the company’s stock in a transaction dated Tuesday, October 8th. The stock was sold at an average price of $48.02, for a total value of $249,704.00. Following the completion of the sale, the director now owns 13,065 shares of the company’s stock, valued at approximately $627,381.30. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Revolution Medicines Price Performance

NASDAQ RVMD opened at $50.48 on Friday. The stock has a market capitalization of $8.43 billion, a PE ratio of -13.87 and a beta of 1.43. The business has a 50 day simple moving average of $44.10 and a two-hundred day simple moving average of $40.65. Revolution Medicines, Inc. has a 1-year low of $15.44 and a 1-year high of $51.00.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.04). The firm had revenue of $1.00 million during the quarter, compared to analyst estimates of $0.81 million. Revolution Medicines’s revenue was down 73.8% on a year-over-year basis. During the same period last year, the firm earned ($0.92) earnings per share. On average, analysts anticipate that Revolution Medicines, Inc. will post -3.35 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of RVMD. Susquehanna Fundamental Investments LLC purchased a new stake in Revolution Medicines in the 1st quarter worth about $6,656,000. Mass General Brigham Inc purchased a new stake in Revolution Medicines in the 1st quarter worth about $10,900,000. Vanguard Group Inc. raised its position in Revolution Medicines by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 14,757,112 shares of the company’s stock worth $475,622,000 after purchasing an additional 122,721 shares during the period. Seven Eight Capital LP purchased a new stake in Revolution Medicines in the 1st quarter worth about $2,208,000. Finally, BVF Inc. IL raised its position in Revolution Medicines by 50.2% in the 4th quarter. BVF Inc. IL now owns 5,981,212 shares of the company’s stock worth $171,541,000 after purchasing an additional 2,000,000 shares during the period. 94.34% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

RVMD has been the subject of several research analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $61.00 target price on shares of Revolution Medicines in a research report on Monday, October 7th. Wedbush reiterated an “outperform” rating and set a $59.00 target price on shares of Revolution Medicines in a research report on Thursday, August 8th. HC Wainwright reiterated a “buy” rating and set a $56.00 target price on shares of Revolution Medicines in a research report on Monday, August 12th. Oppenheimer increased their target price on Revolution Medicines from $45.00 to $55.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 16th. Finally, Bank of America increased their target price on Revolution Medicines from $48.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, July 16th. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $54.00.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.